Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis

Launched by BOEHRINGER INGELHEIM · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Spesolimab, which is being used to treat patients in Korea who have flare-ups of a skin condition known as generalized pustular psoriasis (GPP). The goal of the trial is to monitor how safe and effective Spesolimab is for patients receiving it in a regular healthcare setting. This means researchers want to see how well the treatment works and if there are any side effects when used in everyday practice.

To be eligible for the trial, participants must be at least 19 years old and starting Spesolimab for the first time. They should also be experiencing a flare-up of GPP. It's important to note that those who have severe allergies to Spesolimab or have significant active infections will not be included in the study. Although the trial is not yet recruiting participants, those who join can expect close monitoring during their treatment to ensure their safety and to assess how well the medication is helping their condition.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
• • Patients with generalized pustular psoriasis (GPP) flare
• • Age \>/=19 years at enrolment
• • Patients who have signed the data release consent form
• Exclusion criteria:
• • Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
• • Patients with clinically important active infections (e.g. active tuberculosis)